Cerenome Secures In-Network Agreement with Blue Cross Blue Shield of Michigan, Expanding CNSide® Contracted Coverage to Approximately 158 Million Covered Lives
Cerenome (CNSY) announced an in-network agreement with Blue Cross Blue Shield of Michigan, expanding CNSide contracted coverage to about 158 million lives.
Rhea-AI Summary
Cerenome (CNSY) announced an in-network agreement with Blue Cross Blue Shield of Michigan, expanding CNSide contracted coverage to about 158 million lives.
The BCBSM contract, effective September 1, 2026, covers approximately 5 million commercial and Medicare Advantage members through Blue Cross Blue Shield of Michigan and Blue Care Network. Together with prior contracts, CNSide now has reimbursement coverage representing about 158 million commercial and Medicare Advantage covered lives, which the company describes as continued execution of its national reimbursement strategy.
CNSide’s CSF Tumor Cell Enumeration assay for leptomeningeal metastases has been used in more than 11,000 tests since 2020 at over 120 U.S. cancer institutions, supported by 12 peer‑reviewed publications and evidence from the FORESEE clinical study.
Positive
- BCBSM in-network agreement effective September 1, 2026, adding about 5 million members
- Contracted reimbursement coverage now represents approximately 158 million commercial and Medicare Advantage covered lives
- Clinical adoption with more than 11,000 CNSide tests performed since 2020
- Institutional footprint across over 120 U.S. cancer institutions
Negative
- None.
Details
Market reaction after BCBSM coverage agreement: CNSY +3.16%
Following this news, CNSY has gained 3.16%, reflecting a moderate positive market reaction. Argus tracked a peak move of +3.3% during the session. Our momentum scanner has triggered 3 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.96. Trading volume is exceptionally heavy at 37.3x the average, suggesting very strong buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- BCBSM covered members
- approximately 5 million members
- Commercial and Medicare Advantage members
- Contracted covered lives
- approximately 158 million covered lives
- Combined commercial and Medicare Advantage coverage
- Agreement effective date
- September 1, 2026
- BCBSM in-network provider agreement
Historical Context
-
HCSC agreement expanded CNSide contracted coverage to approximately 153 million lives
-
CNSide coverage reached 150 million lives alongside reported second-quarter results
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
cerebrospinal fluid (csf) tumor cell enumeration medical
laboratory-developed diagnostic tests technical
in-network provider agreement financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
HOUSTON, Sept. 22, 2026 (GLOBE NEWSWIRE) -- CNSide Diagnostics, LLC, a wholly-owned subsidiary of Cerenome, Inc. (Nasdaq: CNSY) (“Cerenome” or the “Company”), announced today that it has signed an in-network provider agreement with Blue Cross Blue Shield of Michigan (“BCBSM”), effective September 1, 2026, to provide the CNSide® Cerebrospinal Fluid (CSF) Tumor Cell Enumeration (TCE) assay. BCBSM serves approximately 5 million commercial and Medicare Advantage members through Blue Cross Blue Shield of Michigan and Blue Care Network, one of the nation’s largest nonprofit Blue Cross Blue Shield organizations. Combined with previously announced agreements, CNSide has now established contracted reimbursement coverage representing approximately 158 million commercial and Medicare Advantage covered lives, reflecting continued execution of the Company's national reimbursement strategy.
"This agreement with Blue Cross Blue Shield of Michigan represents another important milestone in our commercialization strategy to expand patient access to CNSide," said Marc Hedrick, M.D., President and Chief Executive Officer of Cerenome. "With BCBSM, CNSide now has contracted commercial and Medicare Advantage coverage representing approximately 158 million covered lives, further strengthening our national reimbursement platform and expanding patient access across the U.S."
The BCBSM agreement represents the latest milestone in CNSide’s strategy to establish broad reimbursement coverage across the U.S. Commercial payer coverage is a key driver of physician adoption, patient access, and commercial utilization of laboratory-developed diagnostic tests such as CNSide®.
The CNSide® CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases. The superior clinical utility of CNSide® over standard of care has been shown in 12 peer-reviewed publications and prospective multicenter evidence from the FORESEE clinical study, and has been supported by real-world clinical experience.
Since 2020, more than 11,000 CNSide® tests have been performed at over 120 U.S. cancer institutions, supporting clinical decision-making across academic and community oncology practices nationwide.
This test is available exclusively through CNSide Diagnostics, LLC, as a testing service provided to health care professionals in the U.S.
About CNSide Diagnostics, LLC
CNSide Diagnostics, LLC is a wholly owned subsidiary of Cerenome, Inc. that develops and commercializes proprietary laboratory-developed tests, such as CNSide®, designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The CNSide® CSF Assay Platform enables quantitative analysis of the cerebrospinal fluid that informs and improves the management of patients with leptomeningeal metastases. For more information, visit https://www.cnside-dx.com/.
About Cerenome
Cerenome (Nasdaq: CNSY) is a CNS oncology company advancing an integrated platform that combines precision diagnostics, targeted therapeutics, and artificial intelligence to improve outcomes for patients with central nervous system cancers. The Company’s CNSide® Diagnostics platform supports the detection, molecular characterization, and longitudinal monitoring of CNS cancers through cerebrospinal fluid-based testing. Its lead therapeutic platform, REYOBIQ™ (rhenium Re186 obisbemeda), is being evaluated in clinical trials for leptomeningeal metastases, recurrent glioblastoma, and pediatric brain cancers. The data & artificial intelligence platform is designed to integrate diagnostic, molecular, imaging, and clinical data into actionable insights that support precision oncology and therapeutic innovation. By integrating commercial diagnostics, targeted therapeutics, proprietary longitudinal data, and artificial intelligence within a single organization, Cerenome is building a differentiated CNS oncology platform designed to improve patient care while creating long-term shareholder value, visit https://www.cerenome.com.
About Blue Cross Blue Shield of Michigan
Blue Cross Blue Shield of Michigan, a nonprofit mutual insurance company, is an independent licensee of the Blue Cross and Blue Shield Association. Blue Cross provides health benefits to more than 4.7 million members residing in Michigan in addition to employees of Michigan-headquartered companies residing outside the state. The company has been committed to delivering affordable health care products through a broad variety of plans for businesses, individuals and seniors for more than 80 years. Beyond health care coverage, Blue Cross supports impactful community initiatives and provides leadership in improving health care. For more information, visit bcbsm.com and MiBlueDaily.com.
Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws, including statements regarding clinical trials, expected operations and upcoming developments. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “expect,” “potential,” “anticipating,” “planning” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the potential market for the CNSide CSF Assay, the timing in which the CNSide CSF Assay is commercially launched and commercialization is expanded, revenue and corporate profitability expectations including support reimbursements and payments for the CNSide CSF Assay, the development and utility of the CNSide CSF Assay and expectations as to the Company’s future performance, including the next steps in developing the Company’s product candidates.
Investor Contact
CORE IR
IR@cerenome.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
When does the Blue Cross Blue Shield of Michigan agreement for CNSide take effect?
The in-network provider agreement between CNSide Diagnostics and Blue Cross Blue Shield of Michigan is effective September 1, 2026.
What clinical need does the CNSide CSF assay platform address?
The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases, and is offered as a testing service for U.S. health care professionals.
What evidence supports the clinical utility of CNSide?
The company states that CNSide’s clinical utility versus standard of care has been shown in 12 peer-reviewed publications, prospective multicenter evidence from the FORESEE clinical study, and real-world clinical experience.